American Society for Transplantation and Cellular Therapy Series: #5-Management of Clostridioides difficile Infection in Hematopoietic Cell Transplant Recipients

Transplant Cell Ther. 2022 May;28(5):225-232. doi: 10.1016/j.jtct.2022.02.013. Epub 2022 Feb 22.

Abstract

The Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update its 2009 compendium-style infectious disease guidelines for hematopoietic cell transplantation (HCT). A completely new approach was taken with the goal of better serving clinical providers by publishing each standalone topic in the infectious disease series as a concise format of frequently asked questions (FAQ), tables, and figures. Adult and pediatric infectious disease and HCT content experts developed and then answered FAQs and finalized topics with harmonized recommendations that were made by assigning an A through E strength of recommendation paired with a level of supporting evidence graded I through III. This fifth guideline in the series focuses on Clostridioides difficile infection with FAQs that address the prevalence, incidence, clinical features, colonization versus infection, clinical complications, diagnostic considerations, pharmacological therapies for episodic or recurrent infection, and the roles of prophylactic antibiotics, probiotics, and fecal microbiota transplantation.

Keywords: Clostridioides difficile; Fecal microbial transplant; Graft-versus-host disease; Hematopoietic cell transplant; Infection after transplant.

Publication types

  • Practice Guideline

MeSH terms

  • Adult
  • Cell- and Tissue-Based Therapy
  • Child
  • Clostridium Infections* / therapy
  • Fecal Microbiota Transplantation
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Transplant Recipients
  • United States / epidemiology